IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Kyowa Hakko Kirin subsidiary to acquire Archimedes Pharma

7:35 AM MDT | July 12, 2014 | Natasha Alperowicz

Kyowa Hakko Kirin’s (KHK; Tokyo) subsidiary ProStrakan Group (Galashiels, UK) has agreed with Novo to purchase the entire share capital of Archimedes Pharma (Reading, UK) for £230 million ($393.8 million) in cash. Archimedes is a fast-growing, Europe-based specialty pharmaceutical company providing novel and advanced treatments within the therapeutic areas of pain, oncology, and critical care. Its largest product is PecFent, a nasal spray used to manage breakthrough cancer pain in patients who are already receiving maintenance opioid therapy for...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa